The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care.
Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.
Inclusion Criteria:
Exclusion Criteria:
diana.kwong@ucsf.edu415-514-7371
RASi restart will be deferred to the study participant's providers.
The early restart strategy is to resume RASi as soon as the serum creatinine (SCr) downtrends by ≥0.3mg/dL from peak. In addition, the following criteria must be met: most recent potassium ≤5mEq/L, SCr-based eGFR reported as ≥15 mL/min/1.73m2, and average systolic blood pressure≥120mmHg 12 hours prior to restart. If the study participant is discharged from the hospital before the RASi restart criteria are met, management of RASi restart would be deferred to the discretion of longitudinal outpatient healthcare team.
Artificial Kidney Initiation in Kidney Injury
Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU.
Recovery After Dialysis-Requiring Acute Kidney Injury
A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery
Improving Post Discharge Care After Acute Kidney Injury
Strategy for Uptake of Processes for Recognizing and Responding to Acute Kidney Injury
Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury
The Artificial Kidney Initiation in Kidney Injury 2